At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
Obicetrapib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects.
In Brief
A Phase 2 clinical trial evaluating Obicetrapib and Placebo for Dyslipidemia and 2 related conditions. Completed, enrolled 102 participants across 10 sites.
Detailed Summary
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study in Japanese patients to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia, Hypercholesterolemia, High Cholesterol
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartJun 2022
Primary CompletionMar 2023
Study CompletionApr 2023
TodayJul 2026
First PostedJun 16, 2022
Enrollment StartJun 27, 2022
Primary CompletionMar 24, 2023
Study CompletionApr 21, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 4.0 years ago
Interventions
Obicetrapibdrug
tablet
Placebodrug
No active ingredient